How have DNL shares performed in 2024?

Diurnal Group's stock was trading at GBX 27.30 at the start of the year. Since then, DNL shares have increased by 0.0% and is now trading at GBX 27.30. View the best growth stocks for 2024 here .

How were Diurnal Group's earnings last quarter?

Diurnal Group plc (LON:DNL) issued its quarterly earnings data on Tuesday, September, 15th. The company reported ($4.30) earnings per share for the quarter, topping analysts' consensus estimates of ($6.70) by $2.40.

What other stocks do shareholders of Diurnal Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diurnal Group investors own include Allena Pharmaceuticals (ALNA) , Abercrombie & Fitch (ANF) , Ampliphi Biosciences (APHB) , Cerecor (CERC) , Revolution Lighting Technologies (RVLT) , Spero Therapeutics (SPRO) , SRC Energy (SRCI) , Arbutus Biopharma (ABUS) , Aurora Cannabis (ACBFF) and AcelRx Pharmaceuticals (ACRX) .

How do I buy shares of Diurnal Group?

Shares of DNL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:DNL

Diurnal Group (DNL) Share Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free DNL Stock Alerts

GBX 27.30

0.00 (0.00%)

(As of 10/31/2022)

Compare

Today's Range: 27.30
▼
27.30
50-Day Range: 27.30
▼
27.30
52-Week Range: 9.50
▼
67.90

Volume: 145,283 shs
Average Volume: 483,617 shs
Market Capitalization: £46.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Diurnal Group alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Diurnal Group Stock (LON:DNL)

Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.

DNL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DNL Stock News Headlines

February 6, 2024 | morningstar.com

Da Nang Port Logistics JSC DNL

December 9, 2023 | morningstar.com

D&L Industries Inc

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

August 23, 2023 | investing.com

D&L Industries Inc (DNL)

March 22, 2023 | wsj.com

D&L Industries Inc.

October 28, 2022 | finance.yahoo.com

Form 8.3 - Diurnal Group plc

August 30, 2022 | markets.businessinsider.com

Form 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plc

August 30, 2022 | marketwatch.com

Diurnal Group Agrees to High Premium $56.5 Mln Takeover by Neurocrine Biosciences

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

August 16, 2022 | finance.yahoo.com

Diurnal Group plc (DNL.L)

March 22, 2022 | proactiveinvestors.com.au

AIQ boosted by deal to supply NFT marketplace in Hong Kong

March 22, 2022 | proactiveinvestors.com

Diurnal drops after losses nearly double and it seeks funding

March 22, 2022 | proactiveinvestors.com

Diurnal nosedives on need for further funding

March 9, 2022 | proactiveinvestors.com.au

Diurnal dips as bosses give investor presentation

March 2, 2022 | morningstar.com

Diurnal Group Says Male Hypogonadism Treatment Study to Be Delayed

November 16, 2021 | marketwatch.com

Diurnal Group's Alkindi Drug Approved for Use in Children, Adolescents in Switzerland

November 13, 2021 | finance.yahoo.com

Shareholders May Be More Conservative With Diurnal Group plc's (LON:DNL) CEO Compensation For Now

October 11, 2021 | marketwatch.com

Diurnal Group Ditest Clinical Trial Results Published

September 28, 2021 | markets.businessinsider.com

Hardman & Co Research : Diurnal Group (DNL): All set for three pivotal trials

September 16, 2021 | markets.businessinsider.com

Diurnal Group PLC : Commercial launch of Efmody in the UK

September 16, 2021 | finanznachrichten.de

Hardman & Co Research: Diurnal Group (DNL): All set for three pivotal trials

September 16, 2021 | finanznachrichten.de

Hardman & Co Research: Diurnal Group (DNL): All set for three pivotal trials

September 15, 2021 | finance.yahoo.com

Here's Why We're Not Too Worried About Diurnal Group's (LON:DNL) Cash Burn Situation

August 8, 2021 | markets.businessinsider.com

Diurnal Group PLC : Business and Trading Update

July 24, 2021 | news.yahoo.com

Hartwick Seminary Summer Institute of Theology to mark 30 years

July 22, 2021 | news.yahoo.com

Former Wacker site manager to oversee Chattanooga's Smart Factory Institute at Volkswagen Academy

See More Headlines

Receive DNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diurnal Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/15/2020
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: LON:DNL
CUSIP: N/A
CIK: N/A
Web: www.diurnal.co.uk
Phone: +44-29-20682069
Fax: N/A
Employees: 33
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.77
Current Ratio: 5.23
Quick Ratio: 4.16

Sales & Book Value

Annual Sales: £4.68 million
Price / Sales: 9.89
Cash Flow: GBX 9.70 per share
Price / Cash Flow: 2.81
Book Value: GBX 12.70 per share
Price / Book: 2.15

Miscellaneous

Outstanding Shares: 169,720,000
Free Float: N/A
Market Cap: £46.33 million
Optionable: Not Optionable
Beta: N/A

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Richard Edward Bungay A.C.A. (Age 53)
ACA, B.Sc., BSc, Interim CEO, CFO, Company Sec. & Director
Comp: $338k
Prof. Richard Ross
Chief Scientific Officer & Exec. Director
Mr. Stewart Jones
Operations Director
Mr. John Porter MBBS
Ph.D., Chief Medical Officer
Mr. David Bevan (Age 55)
Chief Bus. Officer

Key Competitors

View All Competitors

DNL Stock Analysis - Frequently Asked Questions

How have DNL shares performed in 2024?: Diurnal Group's stock was trading at GBX 27.30 at the start of the year. Since then, DNL shares have increased by 0.0% and is now trading at GBX 27.30.
View the best growth stocks for 2024 here.
How were Diurnal Group's earnings last quarter?: Diurnal Group plc (LON:DNL) issued its quarterly earnings data on Tuesday, September, 15th. The company reported ($4.30) earnings per share for the quarter, topping analysts' consensus estimates of ($6.70) by $2.40.
What other stocks do shareholders of Diurnal Group own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Diurnal Group investors own include Allena Pharmaceuticals (ALNA), Abercrombie & Fitch (ANF), Ampliphi Biosciences (APHB), Cerecor (CERC), Revolution Lighting Technologies (RVLT), Spero Therapeutics (SPRO), SRC Energy (SRCI), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF) and AcelRx Pharmaceuticals (ACRX).
How do I buy shares of Diurnal Group?: Shares of DNL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:DNL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial